COLO-B Stock Analysis: Coloplast | CO
Medical Instruments & Supplies | CO, Denmark | Market Cap: 94.294m DKK | 12M Return: -20.7% | DK0060448595 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 143M
EPS Trend: -69.7%
Qual. Beats: 0
Rev. Trend: 93.1%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Coloplast A/S is a Denmark-based medical device company headquartered in Humlebæk, founded in 1954. It develops and sells intimate healthcare products across five operating segments: Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics. Its product portfolio serves ostomy, continence, wound, urological/gynecological, laryngectomy, and tracheostomy patients, with well-known brands including SenSura Mio and Brava (ostomy), SpeediCath and Peristeen (continence), Biatain Silicone and Comfeel (wound care), Provox (laryngectomy), and Tracoe (tracheostomy).
As a Health Care Equipment company, Coloplast operates in the medical devices sector, where revenue is typically driven by repeat purchases of consumables such as catheters, ostomy bags, and dressings rather than large one-time equipment sales. This consumable-heavy model generally supports a recurring revenue base, and the company sells directly in major markets including Denmark, the United States, the United Kingdom, and France, as well as internationally.
- US ostomy care pricing pressure and volume growth
- Atos Medical acquisition drives interventional urology revenue
- USD weakness pressures reported Danish kroner earnings
| Net Income: 2.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 2.92 > 1.0 |
| NWC/Revenue: 13.14% < 20% (prev 0.01%; Δ 13.13% < -1%) |
| CFO/TA 0.16 > 3% & CFO 7.67b > Net Income 2.76b |
| Net Debt (24.0b) to EBITDA (11.7b): 2.04 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (225.4m) vs 12m ago -0.01% < -2% |
| Gross Margin: 58.50% > 18% (prev 67.55%; Δ -9.05% > 0.5%) |
| Asset Turnover: 59.99% > 50% (prev 58.20%; Δ 1.79% > 0%) |
| Interest Coverage Ratio: 10.55 > 6 (EBIT TTM 7.35b / Interest Expense TTM 697.0m) |
| A: 0.08 (Total Current Assets 10.4b - Total Current Liabilities 6.66b) / Total Assets 46.9b |
| B: 0.31 (Retained Earnings 14.4b / Total Assets 46.9b) |
| C: 0.16 (EBIT TTM 7.35b / Avg Total Assets 47.4b) |
| D: 0.40 (Book Value of Equity 13.4b / Total Liabilities 33.6b) |
| Altman-Z'' = 2.98 = A |
| DSRI: 0.93 (Receivables 5.07b/5.33b, Revenue 28.4b/27.9b) |
| GMI: 1.15 (GM 67.55% / 58.50%) |
| AQI: 0.95 (AQ_t 0.61 / AQ_t-1 0.64) |
| SGI: 1.02 (Revenue 28.4b / 27.9b) |
| TATA: -0.10 (NI 2.76b - CFO 7.67b) / TA 46.9b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of September 27, 2026, the stock is trading at DKK 417.60 with a total of 362,766 shares traded. Over the past week, the price has changed by -0.19%, over one month by -9.90%, over three months by +9.21% and over the past year by -20.74%.
Current recommended Stop Loss: 403.60 (which is 3.4% or 1.4 ATR below the current price).
Coloplast has no consensus analysts rating.
P/E Trailing = 34.1272
P/E Forward = 15.6006
P/S = 3.3153
P/B = 7.0829
P/EG = 1.0738
Revenue TTM = 28.4b DKK
EBIT TTM = 7.35b DKK
EBITDA TTM = 11.7b DKK
Long Term Debt = 20.2b DKK (from longTermDebt, last quarter)
Short Term Debt = 2.88b DKK (from shortTermDebt, last quarter)
Debt = 24.8b DKK (from shortLongTermDebtTotal, last quarter) + Leases 969.0m
Net Debt = 24.0b DKK (calculated: Debt 24.8b - CCE 817.0m)
Enterprise Value = 118b DKK (94.3b + Debt 24.8b - CCE 817.0m)
Interest Coverage Ratio = 10.55 (Ebit TTM 7.35b / Interest Expense TTM 697.0m)
EV/FCF = 18.86x (Enterprise Value 118b / FCF TTM 6.27b)
FCF Yield = 5.30% (FCF TTM 6.27b / Enterprise Value 118b)
FCF Margin = 22.04% (FCF TTM 6.27b / Revenue TTM 28.4b)
Net Margin = 9.71% (Net Income TTM 2.76b / Revenue TTM 28.4b)
Gross Margin = 58.50% ((Revenue TTM 28.4b - Cost of Revenue TTM 11.8b) / Revenue TTM)
Gross Margin QoQ = 66.73% (prev 42.95%)
Tobins Q-Ratio = 2.52 (Enterprise Value 118b / Total Assets 46.9b)
Interest Expense / Debt = 2.81% (Interest Expense 697.0m / Debt 24.8b)
Taxrate = 30.51% (1.21b / 3.98b)
NOPAT = 5.11b (EBIT 7.35b * (1 - 30.51%))
Current Ratio = 1.56 (Total Current Assets 10.4b / Total Current Liabilities 6.66b)
Debt / Equity = 1.85 (Debt 24.8b / totalStockholderEquity, last quarter 13.4b)
Debt / EBITDA = 2.04 (Net Debt 24.0b / EBITDA 11.7b)
Debt / FCF = 3.82 (Net Debt 24.0b / FCF TTM 6.27b)
Total Stockholder Equity = 14.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.83% (Net Income 2.76b / Total Assets 46.9b)
RoE = 19.69% (Net Income TTM 2.76b / Total Stockholder Equity 14.0b)
RoCE = 21.47% (EBIT 7.35b / Capital Employed (Equity 14.0b + L.T.Debt 20.2b))
RoIC = 12.06% (NOPAT 5.11b / Invested Capital 42.3b)
WACC = 5.59% (E(94.3b)/V(119b) * Re(6.54%) + D(24.8b)/V(119b) * Rd(2.81%) * (1-Tc(0.31)))
Discount Rate = 6.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.25 | Cagr: 0.13%
[DCF] Terminal Value 77.97% ; FCFF base≈5.76b ; Y1≈6.61b ; Y5≈9.72b
[DCF] Fair Price = 589.9 (EV 146b - Net Debt 24.0b = Equity 122b / Shares 207.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -69.69 | EPS CAGR: -9.01% | SUE: 0.23 | # QB: 0
Revenue Correlation: 93.06 | Revenue CAGR: 5.30% | SUE: 1.15 | # QB: 1
EPS current Quarter (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-09-30): EPS=24.81 | Chg30d=+1.60% | Revisions=+55% | GrowthEPS=+39.7% | GrowthRev=+3.5%
EPS next Year (2027-09-30): EPS=26.06 | Chg30d=-0.57% | Revisions=-55% | GrowthEPS=+5.0% | GrowthRev=+6.7%
[Analyst] Revisions Ratio: +0% (up=17, down=17)